The OMA CME reimbursement program has been transferred to the MOHLTC but will still provide financial compensation to qualifying physicians (based on practice postal codes). To get further info click here and to […]
Update on Models of Care, EMR and Ontario Biologics Research Initiative
The ORA has been very busy in its various committees. Check here for important updates on Models of Care, EMR and OBRI. […]
ORA and third party payers
Ontario Rheumatology Association and Private Payers: An update As many of you know, major changes to the reimbursement of biologics via third party payers have been occurring, with many insurance companies providing group […]
OMA agreement: How will it affect you?
ORA Newsletter Winter 2013 OMA Update Our new contract runs until March 2014. It is an improvement on the government’s threatened unilateral changes. The main changes impacting on rheumatology are: 1. An across […]
CRA update to Health Canada’s advisory on concomitant methotrexate and PPIs
The Canadian Rheumatology Association has released an update concerning the recent advisory from Health Canada on the concomitant use of Methotrexate and PPIs. An amended release has been made suggesting that the alert […]
Quick facts October 2012
Latest News: Don’t forget to renew your membership now for 2013. Prices go up November 1st, 2012 1. Aclasta now available for osteoporosis with limited use code 436. For the treatment of osteoporosis […]
Sad news of Dr. Hugh Smythe’s passing
Sad news of Dr. Hugh Smythe’s passing on October 14, 2012 was received today. Dr. Smythe was an internationally known rheumatologist based at the University of Toronto who helped to guide the Division […]
Upcoming Rheumatology EMR User Forums
Sign up and attend a Rheumatology EMR user forum! Forums are planned to give users an opportunity to meet and share best practices, as well as discuss additional tools that may be needed. […]
New Limited Use Code for Zolendronic Acid
436 For the treatment of osteoporosis in postmenopausal women who would otherwise be eligible for funding for oral bisphosphonates, but for whom bisphosphonates are contraindicated due to abnormalities of the esophagus (e.g. esophageal […]
